Concentrate safety and efficacy.
作者信息
Kasper C K
机构信息
Orthopaedic Hospital, 2400 South Flower Street, Los Angeles, CA 90007, USA.
出版信息
Haemophilia. 2002 May;8(3):161-5. doi: 10.1046/j.1365-2516.2002.00601.x.
Abstract
Safety from transmission of infections through plasma-derived clotting factor concentrates is assured by improved donor screening, serological testing of individual donations and direct viral testing of small plasma pools. Modern viral-inactivation techniques are highly effective. Recombinant concentrates stabilized in human albumin are being superaeded by those with other stabilizers. Recently reported discrepancies between estimates of concentrate potency from in vitro assays versus in vivo recovery, depending upon type of assay and reference standard used, are not fully resolved.
摘要
相似文献
1
Concentrate safety and efficacy.
Haemophilia. 2002 May;8(3):161-5. doi: 10.1046/j.1365-2516.2002.00601.x.
2
Viral safety of plasma-derived factor VIII and IX concentrates.
Blood Coagul Fibrinolysis. 1997 Aug;8 Suppl 1:S19-23.
3
Therapeutic properties and safety of recombinant factor VIII and factor IX.重组凝血因子 VIII 和凝血因子 IX 的治疗特性与安全性。
Pol Arch Med Wewn. 2009 Jun;119(6):403-9.
4
Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
Med J Aust. 1985 Jul 8;143(1):11-3. doi: 10.5694/j.1326-5377.1985.tb122758.x.
5
6
Blood safety and the choice of anti-hemophilic factor concentrate.
Pediatr Blood Cancer. 2007 Jan;48(1):117. doi: 10.1002/pbc.21086.
7
Viral safety issues: plasma-derived factor VIII.病毒安全性问题：血浆源性凝血因子VIII。
Ann Hematol. 1994;68 Suppl 3:S35-6. doi: 10.1007/BF01774528.
8
Why prescribe highly purified factor VIII and IX concentrates?
Vox Sang. 1996;70(2):61-8. doi: 10.1111/j.1423-0410.1996.tb01295.x.
9
Summary of the WHO hearing on the development of product-specific reference materials for coagulation factor VIII and factor IX products.世界卫生组织关于凝血因子 VIII 和因子 IX 产品特定产品参考物质开发的听证会摘要。
Biologicals. 2020 Sep;67:88-93. doi: 10.1016/j.biologicals.2020.07.009. Epub 2020 Aug 23.
10
Virucidal treatment of clotting factor concentrates.
Lancet. 1988 Oct 1;2(8614):782-5. doi: 10.1016/s0140-6736(88)92426-9.
引用本文的文献
1
Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry.采用单维凝胶电泳和质谱法对血浆来源的凝血因子 VIII 进行比较。
Blood Transfus. 2010 Jun;8 Suppl 3(Suppl 3):s98-104. doi: 10.2450/2010.016S.
2
Use of proteomics for validation of the isolation process of clotting factor IX from human plasma.利用蛋白质组学验证从人血浆中分离凝血因子 IX 的过程。
J Proteomics. 2010 Jan 3;73(3):678-88. doi: 10.1016/j.jprot.2009.09.020. Epub 2009 Oct 9.
3
Proteomic characterization of plasma-derived clotting factor VIII-von Willebrand factor concentrates.血浆源性凝血因子 VIII-血管性血友病因子浓缩物的蛋白质组学特征。
Electrophoresis. 2009 Oct;30(20):3636-46. doi: 10.1002/elps.200900270.
Zotero 插件